Hyperkalemia drives suboptimal use of RAASi therapy, which is associated with increased CV risk in HF patients. Prof. Zannad presents trial results with the new potassium binders ZS-9 and patiromer.
Niels Grote Beverborg talks about multiple aspects of iron deficiency without anemia in HF, including outcomes, mechanisms, diagnosis, etiology and treatment options.
Which characteristics increase clinical suspicion for amyloidosis, and how should ATTR-cardiomyopathy, a type of amyloidosis, be diagnosed and treated?
Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.
Two dilemmas in use of sacubitril/valsartan for heart failure patients are discussed in this presentation: Should sacubitril/valsartan be used in HFpEF patients and as initial treatment in HFrEF patients?
The co-chairs introduce the topic of this symposium by explaining that many novel therapies for HFrEF have resulted in difficulties in decision-making for management of these patients. The presentations in this series may help in decision-making in a personalized, case-based approach.